Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.
|Videos|April 12, 2021
Pharmaceutical CEO Leadership: Pharma’s Digital Transformation
While the COVID-19 pandemic has visibly accelerated the adoption of telemedicine and virtual meetings among pharma companies, the wider issue of digital transformation across the entire pharma value chain was perhaps less conspicuous during 2020. This Pharmaceutical CEO Leadership: Pharma’s Digital Transformation virtual roundtable brings together pharma Chief Digital Officers and other leaders in the space to discuss the challenges and opportunities associated with digitizing all aspects of the pharma business.
Advertisement
Advertisement
Related to this article
When tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.
Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.
Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.
Dr. Jay Lalezari of CytoDyn explains why Leronlimab’s circulating tumor DNA results in colorectal cancer represent a unique, mechanism-specific proof of concept rather than a broader template.
Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Advertisement
Advertisement
Trending on PharmExec
1
The US Drug-Pricing Reset: Competing on Net Value
2
Novo Terminates Research Collaboration With Korro Bio
3
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
4
Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
5